Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Table 2 Summary of cost inputs associated with clinical inputs, 2018 U.S. Dollars

Parameter	2018 $US
BAT	$34,500
Heart failure medications, annual (a)
ACE/ARB (b)	$852.00
Beta Blocker	$34.20
Digitalis	$480.00
Diuretics	$144.00
ARNI	$6,109.44
Ivabradine	$5,309.04
MRA (c)	$503.76
Other HF meds	$1,299.32
CV non-HF hospitalization (d)	$6,731.68
Heart failure hospitalizations	$6,293.13
LVAD (e)	$186,954.96
Heart transplant	$173,846.71
BAT specific serious adverse events (f)
Infections	$11,842.98
Prolonged intubation (requiring overnight stay)	$2,527.66
Abx allergic reaction (BAT implanted at later date)	$4,824.03
Heart failure exacerbation	$2,527.66
Acute respiratory failure (consequence of anesthesia)	$10,565.57
Pneumonia resulting in intubation	$5,775.02
Ischemic stroke	$16,635.63

Notes and sources: (a) based on estimated monthly costs for average recommended dosages, extrapolated to represent annual costs; (b) ACE = angiotensin converting enzyme inhibitors, ARB = angiotensin receptor blockers; (c) MRA = mineralocorticoid receptor antagonist; (d) average of all CV non-HF hospitalization (6 month data); CV non-HF hospitalization include the following: Cardiac Arrhythmias/Cardiac Arrest, Hypotension/Syncope, Myocardial Infarction/Angina; (e) LVAD = left ventricular assist device; (f) two other BAT specific serious events [Prolonged Stay due to Dizziness; and Cranial Nerve Stimulation for Localized Neck Pain (341 days post implant)] occurred, but were not associated with any additional costs

ISSN: 1471-2261